Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Operating Expenses: 2022-2024

Historic Other Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Dec 2024 value amounting to $66.7 million.

  • Tonix Pharmaceuticals Holding's Other Operating Expenses fell 12.09% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 81.66%. This contributed to the annual value of $66.7 million for FY2024, which is 155.65% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Other Operating Expenses stood at $66.7 million for FY2024, which was up 155.65% from -$119.9 million recorded in FY2023.
  • Tonix Pharmaceuticals Holding's Other Operating Expenses' 5-year high stood at $66.7 million during FY2024, with a 5-year trough of -$130.3 million in FY2022.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Other Operating Expenses averaged around -$61.2 million, with its median value being -$119.9 million (2023).
  • Data for Tonix Pharmaceuticals Holding's Other Operating Expenses shows a peak YoY skyrocketed of 155.65% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Other Operating Expenses (Yearly) stood at -$130.3 million in 2022, then rose by 8.01% to -$119.9 million in 2023, then spiked by 155.65% to $66.7 million in 2024.